Skip to main content

Main navigation (without target group)

About Sobi
Our Patients
Countries and Products
Investigator Sponsored Studies
News
Careers
Contact Us

Breadcrumb

Home
News

News archive

A news archive from Sobi in North America

News archive

A news archive from Sobi in North America

Sobi and Selecta announce strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout

06/15/2020 - 16:06

Results from pivotal phase 2/3 study of emapalumab in patients with primary HLH published in New England Journal of Medicine

05/07/2020 - 08:28

Sobi publishes report for the first quarter 2020

05/05/2020 - 13:24

Load More

Global News

Results from pivotal phase 2/3 study of emapalumab in patients with primary HLH published in New England Journal of Medicine.

More Global News

Filter by Year

Footer Menu

Cookies
Terms of use

©2021 Sobi, Inc. All rights reserved. PP-11140 6/21PP-11600 6/21

This site contains medical information that is intended for residents of the United States and Canada only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy

DOPTELET is a registered trademark, owned by AkaRx, Inc. and marketed by Sobi Inc. ©2021 Sobi Inc. All rights reserved.

GAMIFANT is a registered trademark, owned by Sobi AG and is marketed by Sobi, Inc. ©2021 Swedish Orphan Biovitrum. All rights reserved.

KEPIVANCE is a registered trademark licensed by Sobi, Inc. or its affiliates. ©2021 Sobi Canada, Inc. All rights reserved.

KINERET is a registered trademark licensed by Sobi, Inc. or its affiliates. ©2021 Sobi, Inc. All rights reserved.

KINERET is a registered trademark licensed by Sobi Canada, Inc. or its affiliates. ©2021 Sobi Canada, Inc. All rights reserved.

ORFADIN is a registered trademark licensed by Sobi, Inc. or its affiliates. ©2021 Sobi, Inc. All rights reserved.

ORFADIN is a registered trademark licensed by Sobi Canada, Inc. or its affiliates. ©2021 Sobi Canada, Inc. All rights reserved.

SYNAGIS® is a registered trademark of Arexis AB c/o Swedish Orphan Biovitrum AB (publ) ©2021 Swedish Orphan Biovitrum. All rights reserved.

TEGSEDI® and AKCEA CONNECT® are registered trademarks of Akcea Therapeutics, Inc. Discovered and developed by Ionis Pharmaceuticals and distributed by Sobi, Inc.

TEGSEDI® and AKCEA CONNECT® are registered trademarks of Akcea Therapeutics, Inc. Discovered and developed by Ionis Pharmaceuticals and distributed by Sobi Canada, Inc.

Please do not modify code below!

Sobi United States
+1 781-786-7370
890 Winter Street
Waltham, MA 02451, USA

Sobi Canada
+1 289-291-3852
1155 North Service Rd. West, Unit #11,
Oakville, Ontario, Canada L6M 3E3

©2021 Sobi, Inc. All rights reserved. PP-11600 6/21

This site contains medical information that is intended for residents of the United States and Canada only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy